TP53 and neuroblastoma: NB exhibits inter- and intra-tumor genetic heterogeneity characterized by abnormal telomere maintenance mechanisms, MYCN amplification, and mutations in the RAS and/or p53 pathways, resulting in poor prognosis (Salemi et al., 2022).